Role of Axumin PET Scan in Germ Cell Tumor

• Status: Completed
• Trial end date: 2019-12-30
• Target enrollment: 0
• Participant gender: Male

Summary

Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center

Criteria

Inclusion Criteria:

• Patients with histologically confirmed NSGCT after orchiectomy who are scheduled to undergo primary RPLND or post-chemotherapy RPLND

• Patients must be over 18 years old and capable and willing to provide informed consent.

• Medically stable as judged by patient's physician.

• Life expectancy must be estimated at > 6 months.

• Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age >70 years).

• Patient must be able to lie still for a 20 to 30 minute PET/CT scan. Patients will be asked if they have problems or issues with lying flat

Exclusion Criteria:

• Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to anti-18F-FACBC are NOT eligible.

• Patients with liver failure are NOT eligible.

• Patients currently undergoing chemotherapy or chemotherapy within two weeks of anti-18F-FACBC PET/CT scan are NOT eligible